Blueprint Medicines (BPMC) Misses Q4 EPS by 2c

Blueprint Medicines (NASDAQ: BPMC) reported Q4 EPS of ($2.65), $0.02 worse than the analyst estimate of ($2.63). Revenue for the quarter came in at $38.78 million versus the consensus estimate of $34.16 million.

For earnings history and earnings-related data on Blueprint Medicines (BPMC) click here.

You May Also Be Interested In

• 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
• 51Talk Online Education Group (COE) Reports Q1 EPS of $0.00
• Medtronic completes $550 million Scientia Vascular acquisition